Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Fuji
Cipla
Covington
QuintilesIMS
Fish and Richardson

Generated: August 25, 2019

DrugPatentWatch Database Preview

Patent: 8,604,014

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,604,014
Title:Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use
Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Belvin; Marcia (South San Francisco, CA), Friedman; Lori (South San Francisco, CA), Hoeflich; Klaus (South San Francisco, CA), Sampath; Deepak (South San Francisco, CA), Vijapurkar; Ulka (South San Francisco, CA), Wallin; Jeffrey (South San Francisco, CA), Johnson; Leisa (South San Francisco, CA), Singh; Mallika (South San Francisco, CA), Patel; Sonal (Basel, GB)
Assignee: Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH)
Application Number:13/109,670
Patent Claims:see list of patent claims

Details for Patent 8,604,014

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Try a Free Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2036-04-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2036-04-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2036-04-30 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) 2036-04-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,604,014

Country Patent Number Publication Date
South Africa 201002475 Jun 29, 2011
World Intellectual Property Organization (WIPO) 2009036082 Mar 19, 2009
World Intellectual Property Organization (WIPO) 2009036082 Nov 19, 2009
United States of America 2009098135 Apr 16, 2009
United States of America 2011223619 Sep 15, 2011
United States of America 2013345217 Dec 26, 2013
United States of America 8247397 Aug 21, 2012
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Teva
Chubb
Queensland Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.